SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis

Oncogene

Volumn 31, Issue 43, 2012, Pages 4619-4629

  Byles, V ^a   Zhu, L ^a   Lovaas, J D ^a   Chmilewski, L K ^a   Wang, J ^a   Faller, D V ^a   Dai, Y ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E cadherin; EMT; metastasis; migration; prostate cancer; SIRT1

Indexed keywords

EPIDERMAL GROWTH FACTOR; HISTONE H3; RNA POLYMERASE II; SIRTUIN 1; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL STRUCTURE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MESENCHYME; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RNA BINDING;

EPITHELIAL-MESENCHYMAL TRANSITION; GENE SILENCING; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; SIRTUIN 1; TRANSCRIPTION FACTORS;

HUMAN PAPILLOMAVIRUS; MUS;

EID: 84867901275     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.612     Document Type: Article

References (47)

1. Mimeault M, Batra SK. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 2006; 27: 1-22. (Pubitemid 43032978)
2. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746. (Pubitemid 37487967)
3. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142. (Pubitemid 43278296)
4. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23: 912-923. (Pubitemid 32972691)
5. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009; 1796: 75-90.
6. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T et al. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. Mod Pathol 1994; 7: 835-841.
7. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant Ecadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 1997; 57: 3189-3193. (Pubitemid 27351734)
8. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 2004; 48: 365-375. (Pubitemid 39360388)
9. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers(). Urol Oncol 2010; 28: 473-479.
10. Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci 2009; 66: 773-787.
11. Sanchez-Tillo E, Lazaro A, Torrent R, M, Vaquero EC, Castells A et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatinremodeling protein BRG1. Oncogene 2010; 29: 3490-3500.
12. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M et al. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68: 2479-2488. (Pubitemid 351521824)
13. Smith J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol 2002; 12: 404-406. (Pubitemid 35239940)
14. Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005; 6: 298-305. (Pubitemid 40516896)
15. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004; 14: 408-412. (Pubitemid 39092697)
16. Guarente L. Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 2007; 72: 483-488.
17. Guarente L, Picard F. Calorie restriction-the SIR2 connection. Cell 2005; 120: 473-482.
18. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009; 69: 1702-1705.
19. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26: 5489-5504. (Pubitemid 47255930)
20. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. Mol Endocrinol 2007; 21: 1745-1755. (Pubitemid 47173788)
21. Dai Y, Faller DV. Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics 2008; 3: 137-149.
22. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 30 kinase/AKT pathways. Oncogene 2005; 24: 7443-7454. (Pubitemid 41637984)
23. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428. (Pubitemid 46809165)
24. Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in EMT and cancer. Oncogene 2008; 27: 6958-6969.
25. Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene 1999; 18: 7274-7279. (Pubitemid 30032106)
26. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002; 62: 1613-1618. (Pubitemid 34408479)
27. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375-2385. (Pubitemid 40546696)
28. Michael E, Israel V. Tail vein assay of cancer metastasis. Curr Protoc Cell Biol 2001: 19.2.1-19.2.7.
29. Kim EJ, Um SJ. SIRT1: roles in aging and cancer. BMB Rep 2008; 41: 751-756.
30. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008; 19: 294-308.
31. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HFM, Schaafsma HE et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52: 5104-5109.
32. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007; 21: 2644-2658. (Pubitemid 47607673)
33. Zhang Y, Zhang M, Dong H, Yong S, Li X, Olashaw N et al. Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 2009; 28: 445-460.
34. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. MiR-200a regulates SIRT1 and EMT-like transformation in mammary epithelial cells. J Biol Chem 2011; 286: 25992-26002.
35. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010; 126: 2575-2583.
36. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67: 6612-6618. (Pubitemid 47105506)
37. Kwon HS, Ott M. The ups and downs of SIRT1. Trends Biochem Sci 2008; 33: 517-525.
38. Cha EJ, Noh SJ, Kwon KS, Kim CY, Park BH, Park HS et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009; 15: 4453-4459.
39. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol 2008; 32: 1523-1531.
40. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011; 42: 204-213.
41. Tseng RC, Lee CC, Hsu HS, Tzao C, Wang YC. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 2009; 11: 763-770.
42. Ellis AL, Wang Z, Yu X, Mertz JE. Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J Virol 84: 6139-6152.
43. Dai Y, Ngo D, Forman LW, Qin DC, Jacob J, Faller DV. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol 2007; 21: 1807-1821. (Pubitemid 47173793)
44. Lacher MD, Shiina M, Chang P, Keller D, Tiirikainen MI, Korn WM. ZEB1 limits adenoviral infectability by transcriptionally repressing the Coxsackie virus and Adenovirus Receptor. Mol Cancer 2011; 10: 91.
45. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis 2008; 29: 1725-1733.
46. Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB. Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 2006; 66: 11370-11380. (Pubitemid 46009968)
47. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res 2005; 33: 6566-6578. (Pubitemid 41806421)